Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Blood Group O Found to Be Most Susceptible to Cholera

By BiotechDaily International staff writers
Posted on 18 Sep 2012
The probability of becoming seriously ill from cholera depends on one’s blood group. Recent research showed that it is possible to find a new treatment for this troublesome illness by studying the molecular structure in the toxin in the cholera bacteria.

Three to five million people are infected by cholera yearly. The mortality rate is high: one hundred thousand people die from the infection every year. “Cholera depends on the blood group. Some blood groups have an increased risk of becoming seriously ill,” said Prof. Ute Krengel, from the department of chemistry at the University of Oslo (Norway).

When cholera bacteria multiply in the body, they create a poison called cholera toxin. The toxin must bind to the cell membrane before it can penetrate further into the intestinal cell and create mayhem. By studying the molecular structure of cholera toxins, researchers can discover how the toxins bind to intestinal cells at the level of the atom. Prof. Krengel’s goal was to find a new drug that prevents the cholera toxin from binding to the intestine and that ensures that the toxin is harmlessly dispersed from the body.

Cholera leads to violent diarrhea. The patient can lose up to 12 L of fluid every 24 hours. The treatment is a saline fluid replacement. “It must be administered as soon as possible and in large quantities. If the patient is unconscious already, the saline solution must be given intravenously. Antibiotics are of no use,” explained Prof. Gunnar Bjune, from the Institute of Health and Society at the University of Oslo.

The cholera bacterium is originally from Bangladesh, but in the past 200 hundred years, it has spread to much of the world and has established a firm foothold in many Asian and African countries. “Patients with blood group O are most at risk of becoming seriously ill. Those with blood groups A, B or AB are more protected against cholera,” said Prof. Krengel.

The Bangladeshi population is evenly distributed between blood groups O, A, and B. In Africa, most people have blood group O. Nearly everyone in the indigenous population in Latin America have group O. When cholera hits these areas, it hits especially hard. In collaboration with the Oslo University Hospital and the Biotechnology Centre, Prof. Krengel’s research group examined whether the probability of becoming seriously ill with cholera depends on blood groups. By studying the molecular structure in the toxin in the cholera bacterium, it is possible to find a new remedy for the dreaded illness, determine how strongly the cholera toxin binds, how long it takes to bind, and how long it stays bound to receptors on the intestinal cells.

The cholera toxin binds to small receptors on the intestinal wall. The receptors consist of small straws with attached sugar molecules. They are to protect the cells against harmful intruders. Unfortunately, the receptors can be exploited. “We want to develop new medicines that bind to the cholera toxin so that it cannot bind to the intestinal cells,” stated Prof. Krengel. The cholera toxin consists of two parts. The researchers study the lower part, which binds to the receptors. “We have discovered that the cholera toxin binds differently than previously thought,” she noted. The investigators will now examine how important the various amino acids are in the binding process and which amino acids bind the most. To penetrate into the intestinal cells, the cholera toxin must first get through mucous layer. “Our results suggest that the cholera toxin uses longer to penetrate the mucous layer if the patients have blood group antibodies in the mucous. Four out of five people have blood group antibodies in the mucous. Those with blood group O are the least protected and therefore get sicker than others.”

In its advanced research, the researcher have created a biologic model of how the cholera toxin enters intestinal cells. They do not use real cholera bacteria. Doing so would be too hazardous. Instead, they use Escherichia coli bacteria, which is the primary model bacterium for cell biologists. “They are easy to make and much quicker and safer to work with. We must grow large quantities in order to study the bindings,” said PhD candidate Julie Heggelund, whose background is in molecular biology.

To create synthetic cholera toxins-or to be precise: to create the lower part of the toxin--the scientists must manipulate the genes in E. coli bacteria. When Prof. Krengel had produced the lower part, she killed the bacteria in a pressure cooker. The receptors are synthetic sugar molecules. Microscopes are of no use in finding the structure of the cholera toxin and receptors: the resolution is not good enough. Researchers must rely on X-rays, which have such a short wavelength that most penetrate empty space in molecules. However, before they can get started with the X-ray machine, the researchers must crystallize the toxin and receptor molecules.

By interpreting the X-rays that are spread by the crystal, researchers can calculate what the structure of the atom looks like. This can be compared to sending laser light through a sieve. Studying the light that is spread by the mesh of the sieve allows researchers to calculate what the sieve looks like.

Each exposure is two-dimensional (2D). To create a three-dimensional image, researchers irradiate the toxin crystal up to 500 times from different angles. Although the imaging only takes a few days, the interpretation of the molecular structure can take several months.

Related Links:

University of Oslo




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.